-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
MTD reported strong Q1 results with adjusted EPS of $8.91, up 9% Y/Y and $0.20 above consensus, while total sales reached $947.1M, up 7% reported and 3% in local currency terms. Organic growth was 1%, with laboratory sales rising 1% (55% of total), industrial sales up 5% (40% of total), and food retail growing 7%. Despite an uncertain macroeconomic environment and challenges facing life sciences tools firms, we view this as strong performance demonstrating MTD's resilience. MTD raised full-year 2026 adjusted EPS guidance to $46.30-$46.95 from $46.05-$46.70, representing 8% to 10% growth. Regional performance showed mixed results, with Asia/Rest of World leading at 5% local currency growth, while Americas and Europe posted gains of 2% and 1% respectively. Adjusted operating margin declined ~80 bps to 26.0% due to higher R&D expense and weaker gross margin. In our view, the geographic variation reflects uneven global recovery patterns that MTD continues to navigate.